



FORM PTO 1449a B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICATION NO.: 09/768,012	ATTY. DOCKET NO.: C01040.70010.US
	FILING DATE: January 22, 2001	CONFIRMATION NO.: 9273
	APPLICANT: Heather L. Davis et al.	
	GROUP ART UNIT: 1632	EXAMINER: [RECEIVED]
Sheet 2 of 2		

C91	Daheshia et al., <i>Vaccine</i> , 16(11/12):1103-1110, 1998	
C92	Diamantstein	
C93	Ewel et al., <i>Cancer Res.</i> , 52(11):3005-3010, 1992	
C94	Fynan et al., <i>Proc Natl Acad Sci USA</i> , 90(24):11478-11482, 1993	
C95	Gao et al., <i>Mol Pharmacol</i> , 41:223-229, 1992	
C96	Hadden et al., <i>JAMA</i> 268(20):2964-2969	
C97	Hartmann, <i>Antisense & Nuc. Acid Drug Dev.</i> , 6:291-299, 1996	
C98	Hatzfeld, J., <i>J Exp Med</i> 174:925-929, 1991	
C99	Hefeneider, <i>Clin. Immunol. and Immunopath.</i> , 63(3):245-251, 1992	
C100	Hughes, <i>Antisense Res. & Dev.</i> , 4:211-215, 1994	
C101	Ishikawa, et al., <i>J. Immunol</i> , 150(9):3713-3727, 1993	
C102	Iverson et al., <i>Antisense Research and Development</i> , 4:43-52, 1994	
C103	Johnson, <i>Immunophar & Infectious Diseases</i> , 291-301, 1987	
C104	Karlin et al., <i>J of Virol</i> , 2889-2897, 1994	
C105	Kataoka, et al., <i>Jpn J. Med Sci. Bio</i> , 43:171-182, 1990	
C106	Kern et al., <i>Antimicrob. Agents & Chemo.</i> , 7(6):721-876(1975)	
C107	Khan, <i>Surgery</i> , 118:531-538, 1995	
C108	Krown, S.E., <i>Semin Oncol.</i> , 13(2):207-217, 1986	
C109	Kuramoto et al., <i>Jpn. J. Cnccr Res.</i> , 83:1128-1131, 1992	
C110	Kuramoto et al., <i>Microbiol. Immunol.</i> , 33(11):929-940, 1989	
C111	Kuramoto et al., <i>Int. Immuno-pharmacol.</i> , 14(5):773-782, 1992	
C112	Lacour, et al., <i>J. Biol. Resp. Mod.</i> , 4:538-543, 1985	
C113	Levine et al., <i>Cancer Treat. Rep.</i> , 62(11):1907-1913, 1978	
C114	Levy et al., <i>J. Inf. Disease</i> , 133(Supp):A256-A259, 1976	
C115	Lowell, et al., <i>J. of Infec. Disease</i> , 175:292-301, 1997	
C116	Mashiba, et al., <i>Jpn. J. Med. Sci. Biol.</i> , 41:197-202, 1988	
C117	Michelson et al., <i>Proc. Soc. Exper. Biol. and Med.</i> , 179:180-186, 1985	
C118	Park et al., <i>J. Immunopharm.</i> , 17(6):513-515, 1995	
C119	Pisetsky, <i>Antisense Research and Development</i> , 5(3):219-225 (1995)	
C120	Stull et al., <i>Pharmaceutical Res.</i> , 12(4):465-483, 1995	
C121	Threadgill, et al., <i>Vaccine</i> , 16(1):76-82, 1998	
C122	Tursz et al., <i>Immuno. Prospects of Infectious Diseses</i> , 263-272, 1990	
C123	Uhlmann et al., <i>Chemical Reviews</i> , 90(4):543-584, 1990	
C124	Wiltout, et al., <i>J. Biol. Resp. Mod.</i> , 4(5):512-7, 1985	
C125	Xin, et al., <i>Immunology</i> , 94:438-444, 1998	

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]